ReviewDer Urologe. Ausg. A2020

[Radium-223 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) : The androgen receptor-independent active agent in the therapeutic sequence].

F König et al.PubMed ↗Publisher ↗

No numbers read from the abstract.